EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Shigella Vaccines: The Continuing Unmet Challenge

Ti Lu, Sayan Das iD, Debaki R Howlader iD, William D Picking iD, Wendy L Picking

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25084329 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Ti Lu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Veterinary Pathobiology and Bond Life Science Center, University of Missouri, Columbia, MO 65201, USA. Hauptthemen laut MEDLINE: Shigella Vaccines, Dysentery, Bacillary, Shigella. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 172 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Shigellosis is a severe gastrointestinal disease that annually affects approximately 270 million individuals globally. It has particularly high morbidity and mortality in low-income regions; however, it is not confined to these regions and occurs in high-income nations when conditions allow. The ill effects of shigellosis are at their highest in children ages 2 to 5, with survivors often exhibiting impaired growth due to infection-induced malnutrition. The escalating threat of antibiotic resistance further amplifies shigellosis as a serious public health concern. This review explores Shigella pathology, with a primary focus on the status of Shigella vaccine candidates. These candidates include killed whole-cells, live attenuated organisms, LPS-based, and subunit vaccines. The strengths and weaknesses of each vaccination strategy are considered. The discussion includes potential Shigella immunogens, such as LPS, conserved T3SS proteins, outer membrane proteins, diverse animal models used in Shigella vaccine research, and innovative vaccine development approaches. Additionally, this review addresses ongoing challenges that necessitate action toward advancing effective Shigella prevention and control measures.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Shigella VaccinesDysentery, BacillaryShigellaHumansAnimalsVaccines, SubunitVaccine DevelopmentVaccines, Attenuated

Stichwörter der Autor:innen

Shigella spp.conjugatelive attenuatedshigellosissubunittype III secretion systemvaccineswhole killed

Substanzen

Shigella VaccinesVaccines, SubunitVaccines, Attenuated

Autor:innen und Institutionen

  • Department of Veterinary Pathobiology and Bond Life Science Center, University of Missouri, Columbia, MO 65201, USA.
  • Department of Microbial Pathogenesis, School of Dentistry, University of Maryland, Baltimore, MD 21201, USA.

ORCID-Profile: Sayan Das, Debaki R Howlader, William D Picking

Förderung

  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Lu, T., Das, S., Howlader, D. R., Picking, W. D., & Picking, W. L. (2024). Shigella Vaccines: The Continuing Unmet Challenge. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25084329

Vancouver

Lu T, Das S, Howlader DR, Picking WD, Picking WL. Shigella Vaccines: The Continuing Unmet Challenge. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25084329

BibTeX
@article{Lu2024,
  author = {Lu, Ti and Das, Sayan and Howlader, Debaki R and Picking, William D and Picking, Wendy L},
  title = {Shigella Vaccines: The Continuing Unmet Challenge},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25084329}
}
Kostenlos starten →